Total pelvic exenteration. A 50-year experience at the Ellis Fischel Cancer Center.
To review a 50-year experience with total pelvic exenteration for treatment of advanced pelvic cancer. Retrospective study with 100% follow-up. Cancer hospital. Two hundred thirty-two patients referred for treatment of advanced pelvic cancer who underwent total pelvic exenteration. Rates of operative mortality, complications, recurrence, and 5-year survival. The morbidity rate was 45%. The operative death rate was 14% during the 50-year period, but decreased from 16.8% in the first three decades to 10% thereafter. Eighty-nine patients (38%) had recurrences. The overall 5-year survival rate was 42%. Operative mortality and morbidity have declined over 50 years, largely because of proper patient selection, increasing experience, and advances in perioperative care. Exenteration has a major role in the treatment of advanced pelvic cancer.